**S3:**

**Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD**

**Johannie du Plessis1**, **Hannelie Korf1&2, Jos van Pelt1,Petra Windmolders1**, **Ingrid Vander Elst1, An Verrijken3**, **Guy Hubens4**, **Luc Van Gaal5**, **David Cassiman1,6**, **Frederik Nevens1,6**, **Sven Francque5**, **Schalk van der Merwe1,6**

1Laboratory of Hepatology, KU Leuven, Leuven, Belgium

2Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium

3Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital,

University of Antwerp, Antwerp, Belgium.

4Department of Abdominal Surgery, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium

5Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.

6 Department of Internal Medicine, Division of Liver and biliopancreatic disorders, KU Leuven, Leuven, Belgium

**S3 Table: Clinical and biochemical characteristics of the patient groups**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **LEAN** | **No NAFL and NAFL** | **NASH** | **NASH with Fibrosis** **(n=16)** | **Cirrhosis** | **p-value** |
| **(n=10)** | **(n=34)** | **(n=41)** | **(n=15)** |
| **Anthropometric and Clinical parameters**  |
| Age (years) | \*\* | 42 ± 10 | 44 ± 10 | 42 ± 12 | 59± 11 | **0.002** |
| Gender (% Male) | \*\* | 12% | 54% | 44% | 56% | **<0.001\*** |
| **Biochemical parameters** |
| ALT (U/L) | 11[9-14] | 24[22-34] | 30[22-39] | 52[25-88] | 39[20-50] | **0.05** |
| AST (U/L) | 25[21-31] | 21 [20-28] | 33[25-51] | 40[26-88] | 54 [35-68] | **<0.001** |
| ALP (U/L) | n.d. | 87[73-106] | 77[69-95] | 81[69-113] | 99 [71-124] | **ns** |
| GGT (U/L) | 17[13-19] | 31[22-49] | 39[34-48] | 37[28-55] | 49 [15-138] | **ns** |
| Ferritin (ng/ml) | 94[82-152] | 62[28-95] | 134[57-217] | 119[53-335] | 289[76-691] | **0.001** |
| Total cholesterol (mmol/L) | 4.1[4.0-5.3] | 5.7[4.8-6.1] | 5.1 [4.5-5.6] | 4.9[4.1-5.7] | 4.0[2.0-4.6] | **0.001** |
| Triglycerides (mmol/L) | 0.8[0.7-1.3] | 1.4[1.1-1.6] | 1.7[ 1.3-2.1] | 1.5[1.1-2.7] | 0.84[0.53-1.08] | **0.002** |
| Fasting glucose (mmol/L) | n.d. | 4.3[4.1-5.0] | 4.7[4.4-5.3] | 5.0[4.4-6.1] | 6.1[5.1-7.7] | **<0.001** |
| C-Reactive Protein (nmol/L) | 0.3[0.3-1] | 0.7[0.5-1.5] | 0.5[0.3-1.3] | 0.9[0.3-1.6] | 7.6[3.9-13.2] | **<0.001** |
| White cell count (x109/L) | n.d. | 8.0[7.2-9.7] | 8.2[6.6-9.0] | 7.8[5.5-10] | 6.1[2.6-7.8] | **ns** |
| Data are given as mean +/- SD when they were shown to have a normal distribution or in case of biochemical parameters, that had a not-normal distribution, as median with [IQR].  |
| Kruskal-Wallis test or Wilcoxon Rank Sum test were used where appropriate to determine differences between groups, a p<0.05 was considered significant. \*) for proportional data the Chi-squared test was used. ns=not significant\*\*) blood samples of adult lean controls were anonymous collected prior to biochemical analysis |